Quick answer: Functional thyroid medicine goes beyond TSH testing to evaluate the complete thyroid axis — free T3, free T4, reverse T3, thyroid antibodies (TPO-Ab, TgAb), and genetic deiodinase polymorphisms — because up to 15% of hypothyroid patients on T4 monotherapy have persistent symptoms from impaired T4→T3 conversion, autoimmune disease activity not captured by TSH alone, or functional patterns that standard care misses entirely.
The Complete Thyroid Axis: Beyond TSH
The thyroid gland produces two hormones: thyroxine (T4, 80–85% of thyroid secretion) and triiodothyronine (T3, 15–20% of direct thyroid secretion). Circulating T4 serves primarily as a prohormone — it is converted peripherally to the biologically active T3 by three deiodinase enzymes (DIO1, DIO2, DIO3), all selenium-dependent. T3 is 3–4 times more potent than T4 at the thyroid hormone receptor (TR-α and TR-β) — the nuclear receptor that, when T3-bound, directly regulates gene expression across virtually every cell type in the body.
TSH (thyroid-stimulating hormone) — produced by the anterior pituitary in response to hypothalamic TRH — is an indirect measure of peripheral thyroid hormone status. TSH operates via negative feedback: as T3/T4 rise, TSH falls; as they fall, TSH rises. However, TSH reflects pituitary T3 status, not peripheral tissue T3 status — a dissociation that becomes clinically significant when:
1. T4→T3 conversion is impaired (DIO2 Thr92Ala polymorphism, selenium deficiency, chronic illness, caloric restriction, cortisol excess, amiodarone, beta-blockers) — TSH may be normal while tissues are functionally T3-deficient. 2. T4 is converted preferentially to reverse T3 (rT3) rather than active T3 — rT3 occupies the thyroid receptor without activating it (a competitive antagonist), producing symptoms of hypothyroidism despite normal TSH and T4. 3. Thyroid hormone resistance at the cellular receptor level (rare but documented THRB mutations, more common functional GR-TH receptor crosstalk under chronic stress). 4. Hashimoto’s thyroiditis causing fluctuating hormone levels that may appear normal on a single TSH measurement but vary dramatically day-to-day.
Hashimoto’s Thyroiditis: Autoimmune Thyroid Disease
Hashimoto’s thyroiditis is the most common autoimmune condition in the developed world — affecting an estimated 5% of the general population and up to 10–15% of women over age 40. It is characterized by: lymphocytic infiltration of the thyroid gland (CD4+ T-helper cells driving CD8+ cytotoxic T-cell thyroid destruction), elevated thyroid peroxidase antibodies (TPO-Ab, present in 95% of Hashimoto’s patients — normal <9 IU/mL, functional medicine concern threshold often used at >30 IU/mL), and anti-thyroglobulin antibodies (TgAb, present in 60–80% of Hashimoto’s patients). Goiter (diffuse thyroid enlargement) is characteristic of Goitrous Hashimoto’s; Atrophic Hashimoto’s produces a small, fibrotic gland.
The antibody burden fluctuates and correlates with inflammation severity — TPO-Ab levels above 500 IU/mL are associated with progressive glandular destruction. Patients can cycle between Hashitoxicosis (transient hyperthyroid phase from follicular rupture releasing stored T4/T3), euthyroid phase, and progressive hypothyroidism as glandular reserve diminishes. A single normal TSH does not exclude Hashimoto’s if antibody testing hasn’t been performed.
Genetic predisposition: HLA-DR3 and HLA-DR4 (strongest associations); CTLA-4 and PTPN22 polymorphisms (T-cell regulatory variants); thyroglobulin gene polymorphisms. Family history is the strongest risk factor — first-degree relatives of Hashimoto’s patients have 3–5x elevated risk. Triggers that unmask genetic predisposition include: postpartum state (postpartum thyroiditis in 5–7% of women — often overlooked as mood disorder), viral infections (Epstein-Barr virus molecular mimicry — EBV EBNA-1 protein homology with thyroid autoantigens was demonstrated by Harber and Chobanian), iodine excess (J-shaped dose-response — both deficiency and excess worsen autoimmune thyroid disease), and interferon therapy for hepatitis C.
The DIO2 Thr92Ala Polymorphism: Why Some Patients Need T3
The Thr92Ala variant of DIO2 (rs225014) is present in approximately 16% of people in homozygous form and 36% in heterozygous form — making it one of the most clinically relevant pharmacogenomic variants for thyroid management. DIO2 is the primary enzyme converting T4→T3 in the brain, heart, pituitary, and brown adipose tissue (organs that cannot use DIO1-generated T3). Thr92Ala produces a functionally impaired DIO2 enzyme with reduced T4→T3 conversion efficiency — estimated 30–40% reduction in enzyme activity in in vitro models.
The landmark clinical study by Torlontano et al. (2008, Journal of Clinical Endocrinology & Metabolism) examined 552 athyreotic patients (post-thyroidectomy on T4 monotherapy): Ala/Ala homozygotes had significantly lower quality of life scores, worse psychological well-being, and reduced weight despite comparable TSH, confirming that DIO2 Thr92Ala produces symptoms on T4 monotherapy not captured by TSH. Panicker et al. (2009, Journal of Clinical Endocrinology & Metabolism) further demonstrated that DIO2 Thr92Ala carriers responded better to T4+T3 combination therapy than T4 monotherapy — the first evidence of pharmacogenomics-guided thyroid management.
Clinical implication: patients with documented Hashimoto’s or hypothyroidism who have persistent symptoms on T4 monotherapy (despite “normal” TSH) should be tested for DIO2 Thr92Ala polymorphism. Carriers benefit from T3 supplementation — either as combination T4/T3 therapy (levothyroxine + liothyronine) or as desiccated thyroid extract (DTE, containing a fixed T4:T3 ratio of approximately 4:1 in the thyroid gland’s natural secretion ratio).
Reverse T3 (rT3): The Functional Hypothyroid Biomarker
Reverse T3 (3,3′,5′-triiodothyronine) is produced by outer-ring deiodination of T4 (the same substrate as active T3) — but by DIO3 rather than DIO2. rT3 is the metabolically inactive isomer that competitively occupies but does not activate the thyroid hormone receptor. Under normal conditions, T4 conversion is predominantly (~40%) to active T3 and (~40%) to rT3 (with the remainder to diiodothyronine). Under stress conditions that activate DIO3 and suppress DIO2 — including critical illness (Peeters et al., 2005), caloric restriction, surgery, cortisol excess, selenium deficiency, and chronic inflammation — the ratio shifts toward rT3 production, creating “euthyroid sick syndrome” (also called low T3 syndrome or non-thyroidal illness).
The free T3:rT3 ratio (functional medicine reference: optimal >20 when both are measured in pg/mL; or T3/rT3 ratio >0.02 when using ng/dL and ng/dL respectively) provides an index of functional T3 availability at the receptor. A low T3:rT3 ratio — even with normal TSH and T4 — suggests functional T3 deficiency driven by excessive T4→rT3 shunting. Clinical scenarios producing this pattern: chronic fatigue, fibromyalgia, post-COVID, burnout, caloric restriction for weight loss, and chronic high-dose corticosteroid use. Treatment: addressing the underlying driver (resolving inflammation, restoring caloric adequacy, treating cortisol dysregulation) is the primary intervention; short-term liothyronine (T3) supplementation can provide symptomatic relief while root causes are addressed.
Selenium and Thyroid Function: The Critical Mineral
Selenium is the most critical mineral for thyroid health — the thyroid gland contains the highest selenium concentration per gram of any organ in the body. Selenium is required for: all three deiodinase enzymes (DIO1, DIO2, DIO3) as selenocysteine-containing oxidoreductases; glutathione peroxidase (GPx1, GPx3, and the thyroid-specific GPx4) — protecting thyroid peroxidase from hydrogen peroxide damage during thyroid hormone synthesis; and thioredoxin reductase — reducing oxidative stress in thyroid follicular cells.
Multiple RCTs demonstrate selenium supplementation (200 μg/day selenomethionine) reduces TPO-Ab titers and improves quality of life in Hashimoto’s thyroiditis. Duntas et al. (2003, European Journal of Endocrinology, n=65, 6 months) showed 200 μg/day selenium reduced TPO-Ab by 36% at 3 months and 55% at 6 months vs. 5.6% in placebo. Mazokopakis et al. (2007, Thyroid, n=80, 6 months) confirmed the antibody reduction and found worsening upon selenium discontinuation — suggesting sustained supplementation is required. The 2015 Cochrane review (van Zuuren et al.) concluded selenium supplementation reduces TPO-Ab at 12 months with possible quality-of-life benefit — supporting routine selenium supplementation for all Hashimoto’s patients with documented deficiency or suboptimal status.
Selenium reference: serum selenium 100–130 μg/L is associated with optimal GPx activity; below 80 μg/L indicates deficiency. Geographic selenium variation is dramatic — selenium in soil determines selenium in crops: Pacific Northwest and Great Lakes regions of the U.S. are low-selenium areas. A single Brazil nut (Bertholletia excelsa) provides 70–90 μg selenium — 1 nut daily is a practical selenium optimization strategy; 2–3 nuts/day achieves target serum levels in most deficient individuals.
Iodine, Goitrogens, and Dietary Considerations
Iodine is the essential substrate of thyroid hormones (T4 = four iodine atoms; T3 = three iodine atoms per molecule). Iodine deficiency causes goiter and hypothyroidism — the reason salt was iodized (1924 Morton Salt initiative, eliminating iodine deficiency in the U.S. Midwest’s “goiter belt”). However, iodine excess — counterintuitively — also causes thyroid dysfunction in susceptible individuals via the Wolff-Chaikoff effect (transient inhibition of thyroid peroxidase by high iodide) and, in Hashimoto’s patients, via iodine-enhanced thyroid antigen immunogenicity. The clinical evidence strongly suggests that Hashimoto’s patients should avoid both iodine deficiency (ensure adequate dietary intake via iodized salt, seafood, dairy) and iodine supplementation beyond physiological needs (avoid kelp supplements and high-dose iodine protocols popularized in alternative medicine circles).
Goitrogens — compounds in raw cruciferous vegetables (broccoli, kale, Brussels sprouts, cabbage, cauliflower) that inhibit thyroid peroxidase via glucosinolate metabolites (isothiocyanates, thiocyanates) — are a source of clinical confusion. The goitrogenic effect of cruciferous vegetables is eliminated by cooking (heat inactivates myrosinase, the enzyme converting glucosinolates to goitrogenic metabolites) and is only clinically significant in the context of concurrent iodine deficiency. Patients with well-treated Hashimoto’s on adequate iodine can freely consume cooked cruciferous vegetables for their Nrf2-activating, cancer-protective sulforaphane content without thyroid concern.
Gluten and Hashimoto’s: The Celiac/NCGS Connection
The association between Hashimoto’s thyroiditis and celiac disease is well-established — celiac disease occurs in 3–5% of Hashimoto’s patients vs. 1% of the general population (4–5x elevated risk). The molecular mimicry hypothesis proposes that gliadin epitopes share structural homology with thyroid antigens — immune responses initiated against dietary gluten subsequently cross-react with thyroid tissue. Ventura et al. (2000, Journal of Pediatrics) demonstrated that strict gluten-free diet in celiac+Hashimoto’s patients reduced thyroid antibody titers and, in some patients, normalized thyroid function — providing mechanistic validation.
Non-celiac gluten sensitivity (NCGS) — defined by gluten-induced symptoms without celiac antibodies or villous atrophy — may also contribute to Hashimoto’s autoimmune activity through intestinal permeability and molecular mimicry mechanisms. A pragmatic 3–6 month gluten elimination trial in all Hashimoto’s patients with symptoms (fatigue, brain fog, GI symptoms) is a low-risk, potentially high-yield intervention regardless of celiac status. Measuring TPO-Ab before and after the elimination trial provides objective evidence of benefit.
Desiccated Thyroid Extract (DTE) vs. T4 Monotherapy
Desiccated thyroid extract (DTH — Armour Thyroid, NP Thyroid, WP Thyroid, Nature-Throid) is derived from porcine or bovine thyroid glands and contains a fixed ratio of T4:T3 (approximately 80:20 T4:T3 by mass, roughly corresponding to the 4:1 molar ratio of thyroid gland secretion). For DIO2 Ala/Ala patients unable to convert T4 to T3 efficiently, DTH’s preformed T3 content may provide clinical benefit unavailable from levothyroxine monotherapy.
Hoang et al. (2013, Journal of Clinical Endocrinology & Metabolism, n=70 hypothyroid patients, crossover RCT) compared Armour Thyroid vs. levothyroxine: 49% of patients preferred DTH (vs. 19% preferring levothyroxine, 33% no preference) — with significantly greater weight loss (3 lbs) and improvements in mood on DTH. Importantly, both treatments produced equivalent TSH levels — confirming the TSH measurement cannot capture the functional difference DIO2-variant patients experience. Peterson et al. (2018, Thyroid) and subsequent analyses confirm the patient-centered benefit of DTH in DIO2-variant hypothyroid patients.
Practical conversion: levothyroxine 100 μg ≈ Armour Thyroid 1 grain (60 mg, containing 38 μg T4 + 9 μg T3). T3 in DTH has a short half-life (8–12 hours vs. 7 days for T4) — twice-daily dosing (morning and noon) provides more stable T3 levels than once-daily dosing. Monitor both TSH and free T3 during DTH therapy — free T3 should remain within normal range (avoid supraphysiologic T3 which can cause atrial fibrillation, bone loss at prolonged exposure, and cardiac hypertrophy).
Low-Level Laser Therapy and Photobiomodulation for Hashimoto’s
An emerging non-pharmacological intervention for Hashimoto’s thyroiditis: low-level laser therapy (LLLT) applied directly to the thyroid gland. The photobiomodulation mechanism involves 830 nm wavelength light activating cytochrome c oxidase in thyroid mitochondria, reducing reactive oxygen species (ROS), suppressing local NF-κB inflammatory signaling, and potentially inducing regulatory T-cell activity in thyroid lymphocytic infiltrates. Höfling et al. (2012, Lasers in Surgery and Medicine, n=43, 10 sessions, 830 nm LLLT): 47% of patients were able to reduce levothyroxine dose or discontinue it at 9-month follow-up vs. 0% in placebo group — a striking result for any non-pharmacological thyroid intervention. TPO-Ab titers decreased 39% in the LLLT group. The study requires replication in larger samples but provides intriguing evidence for adjunct photobiomodulation in Hashimoto’s management.
Frequently Asked Questions About Functional Thyroid Medicine
My TSH is normal but I still have hypothyroid symptoms — what should I test?
Request: free T3, free T4, reverse T3, TPO antibodies, thyroglobulin antibodies, and a complete metabolic panel. Calculate the free T3:rT3 ratio — a ratio below 20 (when both measured in pg/mL) suggests functional T3 deficiency from excessive T4→rT3 shunting. Also evaluate: DIO2 Thr92Ala polymorphism (pharmacogenomic testing), thyroid ultrasound (assesses glandular echogenicity consistent with autoimmune infiltration — the most sensitive imaging marker for Hashimoto’s), and selenium status (serum selenium). Normal TSH does not exclude Hashimoto’s, functional T3 deficiency, or DIO2-variant impaired conversion.
Is Hashimoto’s reversible?
Once established autoimmune thyroid destruction has occurred, lost thyroid tissue is not recovered. However, the autoimmune process can be substantially attenuated — reducing antibody titers, slowing progressive destruction, and occasionally achieving remission with sustained normal antibody levels. Interventions with the strongest evidence for antibody reduction: selenium supplementation (200 μg/day), gluten elimination in celiac or NCGS patients, vitamin D optimization (target 50–70 ng/mL — multiple studies demonstrate inverse correlation between vitamin D status and TPO-Ab titers), low-dose naltrexone (LDN — modulates regulatory T-cell function), and stress management/HPA axis rehabilitation (elevated cortisol suppresses regulatory T-cell populations maintaining immune tolerance).
Should I take iodine for my thyroid?
Adequate iodine (150 μg/day for non-pregnant adults, 220 μg/day during pregnancy) is essential for thyroid hormone synthesis. This is easily met by iodized salt use, dairy consumption (milk contains 50–80 μg iodine per cup from iodophor sanitizers in dairy processing), and seafood. High-dose iodine supplementation (Lugol’s solution, kelp supplements providing 1,000–12,500 μg/day) is contraindicated in Hashimoto’s — iodine excess triggers Wolff-Chaikoff effect and enhances thyroid antigen immunogenicity, potentially accelerating autoimmune thyroid destruction. If you have Hashimoto’s, focus on adequate (not excessive) iodine from food sources.
What is the optimal TSH for someone on thyroid hormone replacement?
Conventional medicine targets TSH 0.5–4.5 mIU/L (normal reference range) for thyroid hormone replacement. Functional medicine practice typically targets TSH 0.5–2.0 mIU/L for optimal symptom management — based on evidence that many patients experience symptom recurrence at TSH values >2.0 mIU/L. For patients with persistent symptoms despite “normal” TSH, focus shifts from TSH target to free T3 optimization: free T3 in the upper third of the reference range (approximately 3.2–4.0 pg/mL when reference is 2.0–4.4 pg/mL) correlates best with subjective well-being, cognitive function, and metabolic rate. Free T3 level should always be evaluated alongside TSH for comprehensive thyroid management.
Persistent thyroid symptoms despite normal TSH deserve thorough functional evaluation — not dismissal. Our functional medicine team at The Private Practice provides complete thyroid axis assessment including DIO2 pharmacogenomics, reverse T3, antibody profiling, and personalized treatment planning including DTH when appropriate. Call us at (810) 206-1402 to schedule a comprehensive thyroid evaluation.